Trial Profile
Efficacy and safety of sublingual immunotherapy with house dust mite extract in asthmatic children: a double-blind, randomized, and placebo-controlled study
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs House dust mite allergy immunotherapy (Primary)
- Indications Allergic asthma
- Focus Therapeutic Use
- 30 Oct 2005 New trial record.